Time to Treatment Initiation Did Not Vary by Race for Advanced Cancers

There was no difference in time to treatment initiation (TTI) by race/ethnicity group for patients diagnosed with a variety of advanced cancers including multiple myeloma (MM), according to a real-world analysis of data from the Flatiron Health electronic health record database.

Teresa M. Zyczynski, MBA, MPH, PharmD, of Bristol Myers Squibb, and colleagues looked at 81,543 patients with advanced non-small cell lung cancer (NSCLC; 37%), metastatic colorectal cancer (mCRC; 19%), metastatic breast cancer (mBC; 15%), MM (8%), advanced gastric cancer (5.2%), advanced urothelial cancer (aUL; 5.2%), metastatic renal cell carcinoma (mRCC; 5%), or advanced melanoma (4.1%). Patients were treated with first-line therapy and had at least one month of follow-up from 2014-2019.

These findings were presented as an abstract at the 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium.

The majority of patients were White (67%), following by “other” race (11%), Black (9%), or Asian (3%) race/ethnicity. TTI was similar across the different race/ethnicity groups, ranging from 1.1 to 1.2 months.

However, the researchers did find that median overall survival varied by tumor and race/ethnicity groups. Multivariable analysis showed that Asian patients had better overall survival than Black patients in many cancers including advanced NSCLC, mBC, advanced gastric cancer, aUL, and mRCC. In contrast, White patients had better survival than Black patients for mBC and advanced gastric cancer. No difference in MM survival were noted.

The researchers noted that given the small sample sizes in some groups of patients, “further analyses are needed to determine the influence of race/ethnicity on cancer care and outcomes.”